SLS – Sellas Life Sciences Group I
Investors holding2
Combined shares380,778
Combined reported value$4.7M
SLS chart by TradingView. Live prices are TradingView's; all other numbers on this page are from 13F filings.
Ownership
| Investor | % of their portfolio | Change | Shares | Reported value | Period |
|---|---|---|---|---|---|
| Polen Capital | 0.03 | New | 218,091 | $2.7M | Q3 2026 |
| Paul Tudor Jones narrow view | 0.01 | New | 162,687 | $2.0M | Q3 2026 |
Activity: last 4 quarters
| Period | Investor | Change | Shares after | Effect on their portfolio (pts) |
|---|---|---|---|---|
| Q3 2026 | Polen Capital | New | 218,091 | 0.03 |
| Q3 2026 | Paul Tudor Jones narrow view | New | 162,687 | 0.01 |
Added: opened or increased
| Period | Investor | Change | Shares after | Effect on their portfolio (pts) |
|---|---|---|---|---|
| Q3 2026 | Polen Capital | New | 218,091 | 0.03 |
| Q3 2026 | Paul Tudor Jones narrow view | New | 162,687 | 0.01 |
Reduced: reduced or closed
No tracked investor reduced or closed this position in the last 4 quarters.
History
Shares held, last 8 quarters
| Investor | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|---|---|
| Polen Capital | 218.1K | – | – | – | – | – | – | – |
| Paul Tudor Jones | 162.7K | – | – | – | – | – | – | – |
– = not held that quarter. n/a = no holdings report for that quarter (not filed yet, or reported under another manager).